Get Your 7-Day Free Trial!
Warning! GuruFocus has detected 1 Severe warning sign with ADPT. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Also Trade In: Germany
Current and historical daily P/E ratio for Adaptive Biotechnologies Corp () from 2019 to Sep 28 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Adaptive Biotechnologies stock (ADPT) PE ratio as of Sep 28 2021 is 0. More Details
Adaptive Biotechnologies PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Adaptive Biotechnologies PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
1551 Eastlake Avenue East, Suite 200, Seattle, WA, USA, 98102
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.